Gabather AB (GABA) AI Stock Analysis

0 Followers

Gabather AB

(Nasdaq OMX AB:GABA)

Select Model

Rating:40Underperform

Price Target:SEK 0.02▼(-5.56% Downside)

Action:reiterated

Date:11/11/26

Gabather AB's overall score of 40 is heavily weighed down by its pre-revenue status, significant cash burn, and absolute reliance on external capital. Although a pristine, debt-free balance sheet provides essential structural safety for an early-stage biotech, the stock is heavily pressured by a deeply negative valuation profile and a strong technical downtrend across all major moving averages.

Positive Factors

Debt-free balance sheetThe absence of reported debt reduces interest expense and debt-service pressure while Gabather advances its CNS drug candidates. This preserves financial flexibility for research spending and limits creditor constraints, although equity funding remains important because the business is still pre-revenue.

Negative Factors

No revenue tractionZero revenue means Gabather has not yet demonstrated commercial demand or a recurring income stream from its drug candidates. The company therefore remains reliant on development progress and future financing rather than internally generated sales, limiting visibility on eventual scale and profitability.

Gabather AB (GABA) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 11.48M
Dividend Yield: ―
Average Volume (3M): 2.45M
Price to Earnings (P/E): -1.1
Beta (1Y): 0.73
Revenue Growth: ―
EPS Growth: 65.27%
Country: Sweden
Employees: 2
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Gabather AB Business Overview & Revenue Model

Company Description

Gabather AB (publ) is dedicated to creating innovative pharmaceutical solutions for a range of central nervous system disorders. The company's focus includes developing medications for conditions such as psychotic illnesses, mood and anxiety disorder...

Gabather AB Financial Statement Overview

Summary

Gabather AB is a pre-revenue clinical drug manufacturer facing persistent net losses and significant cash burn. While the balance sheet benefits from a completely debt-free profile, the company lacks internal funding capabilities and relies entirely on external equity financing to sustain operations.

Income Statement

15Very Negative

Balance Sheet

45Neutral

Cash Flow

10Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0	0	0	0	0	0
Gross Profit	0	0	0	0	0	0
EBITDA	-4.90M	-4.53M	0	37.00K	3,000	-16.91M
Net Income	-5.00M	-4.65M	-7.75M	-9.44M	-8.54M	-17.00M
Balance Sheet
Total Assets	4.54M	3.83M	1.83M	7.36M	6.75M	15.39M
Cash, Cash Equivalents and Short-Term Investments	3.69M	3.14M	878.00K	1.11M	6.27M	14.85M
Total Debt	0	0	0	0	0	0
Total Liabilities	3.08M	4.69M	6.01M	6.88M	3.31M	4.43M
Stockholders Equity	1.46M	-863.00K	-4.17M	486.00K	3.44M	10.96M
Cash Flow
Free Cash Flow	-7.13M	-7.22M	-3.33M	-11.64M	-9.60M	-16.12M
Operating Cash Flow	-7.13M	-7.22M	-3.33M	-11.64M	-9.60M	-16.12M
Investing Cash Flow	0	0	0	0	0	0
Financing Cash Flow	7.82M	9.49M	3.09M	6.49M	1.02M	46.00K

Gabather AB Technical Analysis

Technical Analysis SentimentNegative

Last Price0.02

Price Trends

50DMA0.02Negative

100DMA0.03Negative

200DMA0.03Negative

Market Momentum

MACD-0.00Negative

RSI37.66Neutral

STOCH26.39Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:GABA, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 37.66 is Neutral, neither overbought nor oversold. The STOCH value of 26.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:GABA.

Gabather AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

SE:GABA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:CAMX	78Outperform	SEK 44.75B	58.66	16.50%	―	2.96%	-4.07%
SE:SANION	77Outperform	SEK 1.63B	8.89	29.71%	―	24.98%	-31.44%
SE:BIOA.B	65Neutral	SEK 27.79B	260.50	5.18%	0.69%	-46.09%	-90.13%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:ALZCUR	49Neutral	SEK 899.09M	10.67	65.99%	―	―	―
SE:ORX	42Neutral	SEK 304.20M	-0.08	-115.03%	―	-97.68%	-83.26%
SE:GABA	40Underperform	SEK 11.48M	-1.09	-2479.40%	―	―	65.27%

* Healthcare Sector Average

Performance Comparison

SE:GABA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:GABA	Gabather AB	0.02	-0.01	-33.33%
SE:CAMX	Camurus AB	745.00	123.00	19.77%
SE:ORX	Orexo AB	0.88	-16.72	-95.02%
SE:ALZCUR	AlzeCure Pharma AB	6.40	4.54	243.16%
SE:BIOA.B	BioArctic AB Class B	310.00	25.49	8.96%
SE:SANION	Saniona AB	11.91	-4.31	-26.57%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 11, 2026

Gabather AB AI Stock Analysis